Expertise and infrastructure related to HIV surveillance, clinical trials and molecular diagnostics allowed BHP to be in a unique position to rapidly respond to the COVID-19 pandemic.  BHP partnered with the government to stand up robust SARS CoV2 PCR testing within days of the first diagnosed cases (performing more than 1/3 of testing for the country).  Additionally, the BHP lab created a world-class program for SARS CoV2 genomic surveillance using molecular sequencing which led to the discovery of the omicron variant [https://bhp.org.bw/index.php/inside-lab-identified-omicron].  The clinical trials unit at BHP is conducting COVID-19 vaccine efficacy and effectiveness trials.  Other BHP studies with a focus on COVID-19 include the first large study to show the detrimental impact of co-infection of HIV and COVID on pregnancy outcomes [https://www.aidsmap.com/news/feb-2022/covid-19-raises-risk-adverse-birth-outcomes-especially-women-hiv] and a cohort that is evaluating long COVID in adults/children with and without HIV.